3Abrams p,cardozo L,Fall M,et al,The standardisation of terminology of lower urinary tract function:report from the standardisation subcommittee of the international Continence Society,Neurourol Urodyn,2002,21:167-178.
二级参考文献3
1[1]Colling J.An update on the AHCPR guideline implementation[J].Nurse Practice Forum,1994,5(3):134-137
4DOBREK L, JUSZCZAK K, WYCZOLKOWSKI M, et al. Current management and future perspectives of overactive blad der (OAB) pharmacotherapy[J]. Acta Pol Pharm, 2011,68(6) 807-821.
5MALHOTRA B,GANDELMAN K,SACHSE R, et al. The de- sign and development of fesoterodine as a prodrug of 5-hydroxy- methyl tolterodine(5-HMT),the active metabolite of 101 terod- ine[J]. Curr Med Chem,2009,16(33):4481-4489.
6HOMMA Y, YOSHIDA M, SEKI N, et al. Symptom assess- ment tool for overactive bladder syndrome -- overactive bladder symptom score[J]. Urology, 2006 ,68(2) : 318-323.
7MATZA LS,THOMPSON CL,KRASNOW J, et al. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ) [J]. Neurourol Urodyn,2005,24(3) :215-225.
8LAM S, HILAS O. Pharmacologic management of overactive bladder[J]. Clin Interv Aging,2007, 2(3) : 337-345.
9CARDOZO L. CASTRO-DIAZ D, GITTELMAN M, et al. Re- ductions in overactive bladder-related incontinence from pooled a- nalysis of phase III trials evaluating treatment with solifenacin[J]. Int Urogyneeol J Pelvic Floor Dysfunet, 2006,17 (5) : 512- 519.
10OHTAKE A,UKAI M, HATANAKA T, et al. In vitro and in vivo tissue selectivity profile of solifenaein sueeinate(YM905)for urinary bladder over salivary gland in rats[J]. Eur J Pharmacol, 2004,492 (2-3): 243-250.
